Lilly and Innovent enter drug development collaboration in China

摘要

Eli Lilly and Innovent have announced one of the largest biotech drug development collaborations in China between a multinational and a domestic company. Under the terms of the agreement, the two companies will collaborate to support the development and potential commercialisation of at least three cancer treatments during the next decade. The agreement creates possible new treatment options, while strengthening the presence of both companies in the Chinese oncology market.